Garry E. Menzel - 07 Dec 2022 Form 4 Insider Report for TCR2 THERAPEUTICS INC.

Signature
/s/ Margaret Siegel as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
07 Dec 2022
Net transactions value
-$23,360
Form type
4
Filing time
09 Dec 2022, 15:44:15 UTC
Previous filing
07 Dec 2022
Next filing
13 Dec 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCRR Common Stock Sale $11,680 -9,111 -4.8% $1.28 180,123 07 Dec 2022 Direct F3
transaction TCRR Common Stock Sale $11,680 -9,314 -5.2% $1.25 170,809 08 Dec 2022 Direct F3
holding TCRR Common Stock 132,729 07 Dec 2022 See Footnote F1
holding TCRR Common Stock 132,730 07 Dec 2022 See Footnote F2
holding TCRR Common Stock 189,234 07 Dec 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 132,729 shares of common stock held by the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Menzel Trust"). The reporting person is the trustee of the Menzel Trust, and as such the reporting person may be deemed to beneficially own such securities. The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust.
F2 Consists of 132,730 shares of common stock held by and the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own such securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust.
F3 The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.